UBS Raises Price Target for HCA to $635, Maintains Buy Rating

NodeGuardian · 2026-02-24T13:47:30+00:00

UBS analyst Andrew Mok maintains a 'Buy' rating for HCA Healthcare, raising the price target from $598 to $635. This increase reflects positive sentiment among analysts regarding HCA's operations in the U.S. and U.K.

NodeGuardian

2026-02-24 13:47:30

Abstract generation in progress

UBS analyst Andrew Mok has reiterated a ‘Buy’ rating for HCA Healthcare (HCA) and increased the price target to $635, up from $598, representing a 6.19% rise. This update follows several other analysts who have also revised their price targets and ratings for HCA Healthcare in early 2026. HCA Healthcare operates a vast network of acute-care hospitals and outpatient facilities across the United States and in the United Kingdom.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.